Middletown Life

Author: HAVAS WORLDWIDE – Pittsburgh

Sebela Pharmaceuticals Presents Phase 3 Tegoprazan Data in Erosive Esophagitis at Digestive Disease Week® (DDW) 2026

May 5, 2026
“Invisible millions” with hearing loss missing from mainstream media

March 3, 2026
Havas Health and BrightInsight Forge Exclusive Alliance to Tackle Pharma’s $500B+ Patient Problem

February 26, 2026
Havas CX 2025 X INDEX Report Reveals Growing Gap Between Brand Promises and Customer Reality

January 21, 2026
Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease

January 12, 2026